Webster Santos
Gründer bei SphynKx Therapeutics LLC
Profil
Webster Santos is the founder of SphynKx Therapeutics LLC, which he founded in 2010 and where he holds the title of Vice President-Medicinal Chemistry.
He is currently the President, Chief Executive Officer & Director at Continuum Biosciences, Inc., a position he has held since 2017.
Dr. Santos received his undergraduate and doctorate degrees from the University of Virginia.
Aktive Positionen von Webster Santos
Unternehmen | Position | Beginn |
---|---|---|
SphynKx Therapeutics LLC
SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Gründer | 01.01.2010 |
Continuum Biosciences, Inc.
Continuum Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Continuum Biosciences, Inc. operates as a biotech company that focuses on diseases such as obesity, diabetes, and ageing. The company was founded in 2017 and is headquartered in Blacksburg, VA. | Vorstandsvorsitzender | 15.08.2017 |
Ausbildung von Webster Santos
University of Virginia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
SphynKx Therapeutics LLC
SphynKx Therapeutics LLC Pharmaceuticals: MajorHealth Technology SphynKx Therapeutics LLC engages in developing, discovering and commercializing novel therapies for the treatment of fibrosis. Its Sphingosine 1-phosphate (S1P) is recognized as a key regulator of many of the cellular processes that promote wound healing and fibrogenesis, which include fibroblast and immune cell migration, vascular leak, proliferation, angiogenesis, and TGF-ß signaling. The company was founded by Andrew Bolt, Kevin R. Lynch, Webster Santos and Timothy L. Macdonald in 2010 and is headquartered in Charlottesville, VA. | Health Technology |
Continuum Biosciences, Inc.
Continuum Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Continuum Biosciences, Inc. operates as a biotech company that focuses on diseases such as obesity, diabetes, and ageing. The company was founded in 2017 and is headquartered in Blacksburg, VA. | Commercial Services |